Market closedNon-fractional
Alimera Sciences/ALIM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Alimera Sciences
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.
Ticker
ALIM
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Alpharetta, United States
Employees
157
Website
alimerasciences.com
Alimera Sciences Metrics
BasicAdvanced
$293M
Market cap
-
P/E ratio
-$0.61
EPS
1.15
Beta
-
Dividend rate
Price and volume
Market cap
$293M
Beta
1.15
Financial strength
Current ratio
2.62
Quick ratio
2.335
Long term debt to equity
175.758
Total debt to equity
177.736
Interest coverage (TTM)
-0.08%
Management effectiveness
Return on assets (TTM)
-0.58%
Return on equity (TTM)
-197.04%
Valuation
Price to revenue (TTM)
2.317
Price to book
7.26
Price to tangible book (TTM)
-5.48
Price to free cash flow (TTM)
-2.371
Growth
Revenue change (TTM)
61.75%
Earnings per share change (TTM)
-74.94%
3-year revenue growth (CAGR)
23.84%
3-year earnings per share growth (CAGR)
-25.22%
What the Analysts think about Alimera Sciences
Analyst Ratings
Majority rating from 4 analysts.
Alimera Sciences Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$23M
-12.55%
Net income
-$6.2M
67.57%
Profit margin
-26.95%
91.68%
Alimera Sciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.32
-$0.06
-$0.07
-$0.12
-
Expected
$0.02
-$0.06
-
-$0.06
-$0.04
Surprise
-8,900.00%
-6.98%
-
111.76%
-
Alimera Sciences News
AllArticlesVideos
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM
PRNewsWire·5 hours ago
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. – ALIM
GlobeNewsWire·3 weeks ago
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM
PRNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alimera Sciences stock?
Alimera Sciences (ALIM) has a market cap of $293M as of July 27, 2024.
What is the P/E ratio for Alimera Sciences stock?
The price to earnings (P/E) ratio for Alimera Sciences (ALIM) stock is 0 as of July 27, 2024.
Does Alimera Sciences stock pay dividends?
No, Alimera Sciences (ALIM) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Alimera Sciences dividend payment date?
Alimera Sciences (ALIM) stock does not pay dividends to its shareholders.
What is the beta indicator for Alimera Sciences?
Alimera Sciences (ALIM) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Alimera Sciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.